Early In vitro screening for genotoxicity
- Saves money and improves productivity
- Enables chemists to modify compounds to reduce genotoxicity without losing desirable target bio-activity
Further assays to understand the causes of positive results
- Clearer decision to keep or reject candidate
- Additional information to take forward to In vivo studies
Why screen early?
Recent estimates put the cost of bringing a new Agrochemical product to market in excess of $300M. A process that now sees the generation of approx.140,000 molecules in order to generate one marketable product and in a timescale that has grown from 8 years in 1995 to about 10 years today. In this process the cost and time taken in generating toxicology and environmental fate information has grown substantially.
In order to guard against genotoxic compounds (chemicals that damage or interfere with DNA) being developed into crop protection agents it is a regulatory requirement that compounds undergo safety testing prior to field testing and registration. Such testing becomes more expensive the later it occurs in the process as the cost of rejecting a candidate increases the closer it occurs to field testing.
The very high levels of both sensitivity and specificity achieved with GreenScreen HC and BlueScreen HC, provides a valuable insight into genotoxicity liability; often at a very early screening stage in compound development. This represents a direct and very important benefit when considering the essential requirement to provide laboratory and manufacturing staff personal protection in terms of Health and Safety.
When to Screen
The earlier a compound is screened the greater the cost and time saving. The cost of rejecting a candidate based on genotox screening at the Lead Optimisation stage is more than 10x greater than if it had been rejected at the Profiling stage. In addition, the opportunity to modify the compound, to make it safer, is correspondingly reduced.